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Elevated VMP1 expression in acute myeloid
leukemia ampliﬁes autophagy and is
protective against venetoclax-induced
apoptosis
Hendrik Folkerts1, Albertus T. Wierenga1,2, Fiona A. van den Heuvel1,2, Roy R. Woldhuis1, Darlyne S. Kluit1,
Jennifer Jaques1, Jan Jacob Schuringa 1 and Edo Vellenga1
Abstract
Vacuole membrane protein (VMP1) is a putative autophagy protein, which together with Beclin-1 acts as a molecular
switch in activating autophagy. In the present study the role of VMP1 was analysed in CD34+ cells of cord blood (CB)
and primary acute myeloid leukemia (AML) cells and cell lines. An increased expression of VMP1 was observed in a
subset of AML patients. Functional studies in normal CB CD34+ cells indicated that inhibiting VMP1 expression
reduced autophagic-ﬂux, coinciding with reduced expansion of hematopoietic stem and progenitor cells (HSPC),
delayed differentiation, increased apoptosis and impaired in vivo engraftment. Comparable results were observed in
leukemic cell lines and primary AML CD34+ cells. Ultrastructural analysis indicated that leukemic cells overexpressing
VMP1 displayed a reduced number of mitochondrial structures, while the number of lysosomal degradation structures
was increased. The overexpression of VMP1 did not affect cell proliferation and differentiation, but increased
autophagic-ﬂux and improved mitochondrial quality, which coincided with an increased threshold for venetoclax-
induced loss of mitochondrial outer membrane permeabilization (MOMP) and apoptosis. In conclusion, our data
indicate that in leukemic cells high VMP1 is involved with mitochondrial quality control.
Introduction
Macroautophagy (referred to as autophagy) is a multi-
step catabolic process involved in lysosomal degradation
of redundant cellular constituents, such as organelles and
proteins1–3. Autophagy is essential for hematopoietic
stem cell (HSC) maintenance, in part by actively limiting
mitochondrial oxidative metabolism4,5. During HSC dif-
ferentiation the autophagic-ﬂux gradually declines, but
autophagy might have distinct functions in terminal dif-
ferentiated cells6. It controls the clearance of
mitochondria in erythroid precursor cells and is essential
for monocyte-to-macrophage differentiation7–10. For the
malignant counterpart, studies have shown that a sub-
group of AML cells heavily relies on autophagy for their
survival11–13, whereby increased autophagy is associated
with therapy resistance14–18. The increased autophagy is
observed especially in poor-risk AML11. Since mutations
in autophagy genes have only been observed in the min-
ority of patients19, increased autophagy is most likely
related to other phenomena, such as therapy-induced
changes in their metabolism. Inhibition of autophagy by
knockdown of essential autophagy genes such as ATG5 or
ATG7 impairs AML in vitro cell proliferation and in vivo
engraftment11,16,20. This vulnerability relies on accumu-
lation of (dysfunctional) mitochondria, as evident by the
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increased reactive oxygen species (ROS) production and
the activation of p53-mediated apoptosis11.
Vacuole membrane protein (VMP1) is an additional
autophagy protein residing in the endoplasmic reticulum
(ER) membrane21,22, which can interact with the BH3
domain of Beclin-1, thereby activating autophagy23. The
anti-apoptotic BCL-2 family members can also bind to the
BH3 domain of Beclin-1, resulting in the dissociation of
VMP1 and subsequent inhibition of the autophagic-
ﬂux23,24. Little information is available on VMP1 in
hematopoietic cells, but in solid tumors it has been shown
that VMP1-dependent autophagy can be activated under
stress conditions, such as starvation and hypoxia25,26. We
therefore determined whether VMP1 is essential for
autophagy in normal and malignant hematopoiesis and
whether high VMP1 expression provides survival beneﬁts
for leukemic cells.
The results showed that VMP1 is important for survival
of normal hematopoietic stem cells and progenitor
(HSCP) cells in vitro and in vivo. Moreover, VMP1
expression was signiﬁcantly increased in AMLs. Over-
expression studies and ultrastructurally analysis revealed
that VMP1 is involved in mitochondrial quality control,
thereby protecting cells against oxidative stress. We
concluded that high VMP1 expression increases autop-
hagic ﬂux and the threshold for venetoclax-mediated loss
of MOMP and thereby reducing apoptosis-mediated
cell death.
Material and methods
Isolation and culture of human CD34+ cells
Umbilical cord blood (UCB) obtained from full-term
healthy neonates who were born at the Obstetrics
departments of the Martini Hospital and the University
Medical Center Groningen (Groningen, the Netherlands)
after informed consent. AML blasts derived from per-
ipheral blood cells or bone marrow were obtained from
patients in accordance with the Declaration of Helsinki;
the protocols were approved by the Medical Ethics
Committee of the University Medical Center Groningen
(UMCG). Mononuclear cells (MNC) were isolated from
UCB, or peripheral blood or bone marrow from AML
patients by Ficol density centrifugation, and CD34+ cells
were subsequently isolated with the autoMACS pro-
separator (Miltenyi Biotec, Amsterdam, the Netherlands).
With this method CD34+ cells are puriﬁed twice in order
to yield a high purity (>97%). In addition, for FACS-based
experiments the CD34+ fraction was selected using
CD34+ markers. AML patient characteristics are indi-
cated in supplemental Table S1. Monoclonal antibodies
CD34, CD123, MPO, CD33, HLA-Dr, CD13, CD14,
CD15, CD36 were used for determination of the AML
phenotype.
Cell culture
Primary AML, normal bone marrow or CB-derived
CD34+ cells (with a CD34+ purity of >97% after isolation)
were cultured in suspension or in T25 ﬂasks pre-coated
with MS5 stromal cells in Gartners medium: Alpha-MEM
(Lonza, Leusden, the Netherlands) supplemented with
12.5% FCS and 12.5% Horse serum (Sigma-Aldrich, Saint
Louis, USA), 1% penicillin/streptomycin (PAA Labora-
tories, Dartmouth, USA), 1 µM hydrocortisone (Sigma-
Aldrich), 57.2 μM β–mercaptoethanol, and cytokines: G-
CSF, Human TPO agonist; Romiplostim (Amgen, Breda,
the Netherlands) and IL-3 (20 ng/mL each). The relative
increase in Cyto-ID signal after overnight incubation with
20 µM hydroxychloroquine (HCQ) was deﬁned as the
autophagy ﬂux6,11. The concentration and incubation
time of HCQ for measuring autophagic-ﬂux was validated
and is based on maximal accumulation of autophago-
somes, without affecting cell viability, after overnight
incubation with HCQ6,11. The leukemic cell lines HL60,
OCIM3, MOLM13 and THP1 were obtained from ATCC
and the cell lines were all tested mycoplasma free by PCR.
All leukemic cell lines cells were cultured in RPMI 1640,
supplemented with 10% FCS and 1% penicillin/
streptomycin.
Antibodies and reagents
The following anti-human antibodies were used: mouse
anti-SQSTM1/p62 (sc-28359) and rabbit (sc-130656) or
mouse (sc-47778) anti-Actin, from Santa Cruz (Santa
Cruz, CA, USA), Mouse anti-LC3 (5F10, 0231-100) from
Nanotools (Munich, Germany), P62, and anti-BCL-2
(Santa Cruz, CA, USA), anti-TOM20 and anti-VMP1
were obtained from cell signalling (Leiden, the Nether-
lands), Hydroxychloroquine (HCQ), was obtained from
Sigma-Aldrich. Venetoclax/ABT-199 (BCL-2 inhibitor,
Selleckchem Munich, Germany), S63845 (MCL-1 inhi-
bitor) was obtained from APExBIO (Boston, MA, USA).
The pan caspase inhibitor ZVAD-FMK was obtained from
(Enzo Life Sciences, Bruxelles, Belgium).
Mitochondrial copy number assay
Total DNA was isolated from >1 × 105 cells using
RNeasy mini kit (Qiagen, Venlo, the Netherlands).
Obtained total DNA was real-time ampliﬁed in iQ SYBR
Green Supermix (Bio-Rad) with the CFX connect Ther-
mocycler (Bio-Rad). The nuclear genes GAPDH and B2M
or mitochondrial genes 12S and tRNA were ampliﬁed.
The obtained CT values were corrected for the corre-
sponding calculated primer reaction efﬁciencies. Based on
the corrected CT values, the mtDNA copy number was
calculated relative to nuclear DNA copy number27. The
primer sequences are listed in the Supplemental Table S2.
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Virus production and transduction of CD34+ leukemic cells
or cell lines
Five lentiviral plasmids with short hairpin RNA
(shRNA) targeting VMP1 were obtained from GE
Healthcare Dharmacon. The shRNAs were cloned into a
pLKO.1-mCherry lentiviral vector using MunI & SacII
restriction enzymes (Thermo Scientiﬁc). After initial
testing, two shRNAs (Clone ID TRCN0000135158 and
TRCN0000138386) were selected for this study based on
effective knockdown efﬁciency. A shRNA sequence that
does not target human genes (referred to as scrambled)
was used as a control. Lentiviral virions were produced by
transient transfection of HEK 293 T cells with pCMV and
VSV-G packing system using Polyethylenimine (Poly-
science Inc. Eppelheim, Germany) or FuGENE (Promega,
Leiden, the Netherlands). Retroviral virions containing
pBABE-puro-mCherry-EGFP-LC3B were produced as
described earlier11. Viral supernatants were collected and
ﬁltered through a 0.2-μm ﬁlter and subsequently con-
centrated using Centriprep Ultracel YM-50 centrifugal
ﬁlters (Millipore, Amsterdam, The Netherlands). CD34+
cells were seeded in Gartners medium supplemented with
cytokines (speciﬁed previously). Transduction was per-
formed by adding 0.5 mL of ~10 times concentrated viral
supernatant to 0.5 mL of medium containing 0.5 × 106
cells in the presence of 4 μg/mL polybrene (Sigma-
Aldrich).
ATP assay
Luminescent ATP Detection Assay Kit (Abcam,
Cambridge, UK, ab113849) was used to measure the levels
of ATP, according to the manufacturer’s protocol.
Gene ontology (GO) analysis in AML
Publicly available data of two large AML expression
datasets with 460 (GSE689128 and 173 (TCGA dataset29,
samples, respectively, was analysed using the R2 Geno-
mics Analysis and Visualization Platform (http://r2.amc.
nl). Gene expression data of all genes was correlated with
VMP1 expression. Correlations with a p-value of ≥.01
and/or with a correlation coefﬁcient of r= ≤.25 were
discarded. Next, genes which positively or inversely cor-
related with VMP1 expression in both AML datasets were
compared. In total 551 (26.8% overlap) positively corre-
lating genes and 979 (24.1% overlap) inversely correlating
genes were present in both datasets. Gene ontology ana-
lysis, using David, was performed on the overlapping
positively or inversely correlating genes.
Electron microscopy
The experimental procedure for ultrastructural analysis
of hematopetic cells has been described previously30. In
brief, FACS sorted OCIM3 cells transduced with pRRL-
blueberry or pRRL-VMP1-blueberry and OCIM3 cells
transduced with shSCR-mCherry or shVMP1-mCherry
were pelleted and subsequently ﬁxed in 2% paraf-
ormaldehyde and 2% gluteraldehyde in 0.1M cacodyla-
date buffer for 24 h at 4 °C. After ﬁxation the cells were
washed in in 0.1M cacodyladate buffer. Cells were stained
with Evans blue and subsequently embedded in low
melting point agarose, as described previously31. Agarose
pieces containing the cell pellet were dehydrated, osmi-
cated, and embedded in Epon according to routine pro-
cedures. Semi-thin sections (0.5 mm) stained with
toluidine blue were inspected using light microscopy to
select for OCIM3 cells. Ultra-thin sections (60–80 nm)
were cut and stained with 4% uranyl acetate in water,
followed by Reynolds lead citrate. Images were taken with
a Zeiss Supra55 in STEM (Oberkochen, Germany) mode
with ATLAS software developed by Fibics (Ottawa,
Ontario, Canada) and the CM100 (Eindhoven, the
Netherlands).
In vivo transplantations into NSG mice
Twelve- to thirteen-week-old female NSG (NOD.Cg-
Prkdcscid IL2rgtm1Wjl/SzJ) mice were purchased from
the Central Animal Facility breeding facility within the
UMCG. Mouse experiments were performed in accor-
dance with national and institutional guidelines and all
experiments were approved by the Institutional Animal
Care and Use Committee of the University of Groningen
(IACUC-RuG). The experiment was performed as
described previously6.
Statistical analysis
An unpaired two-sided Student’s t-test or a Mann
Whitney U test was used to calculate statistical differ-
ences. A p-value of <.05 was considered statistically
signiﬁcant.
All tables, additional material and methods sections and
supplemental ﬁgure legends are available as supplemental
information
Results
VMP1 expression is increased in a subset of CD34+ AML
cells
We previously performed transcriptome analysis on a
publicly available gene expression database of normal
HSPCs and AML cells (Bloodspot expression database32),
with a focus on autophagy associated genes. This showed
that several core-autophagy genes were differentially
expressed in AML compared to normal HSPCs11. Further
analysis revealed that putative autophagy protein VMP1
was expressed at signiﬁcantly higher levels in AMLs
compared to normal HSPCs (Fig. 1a). In contrast, the
expression of the known VMP1 interaction protein
Beclin-1 was not different between AML and normal
HSPCs (Fig. 1a). The elevated expression of VMP1 was
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validated by quantitative polymerase chain reaction
(qPCR), whereby the highest VMP1 expression was
observed in CD34+ AMLs with a monocytic phenotype
(Fig. 1b). Based on the VMP1 levels in Fig. 1b, AMLs with
low or high VMP1 expression were selected for western
blot analysis to determine VMP1 protein levels. Western
blot analysis conﬁrmed variable protein levels of VMP1 in
primary AML CD34+ cells (n= 9, Fig. 1c). In addition
VMP1 mRNA levels signiﬁcantly correlated (R= 0.6703,
p= < .01) with VMP1 protein levels (Fig. 1d, AML (n= 9),
CB CD34+ cells (n= 2) and normal bone marrow (NBM)
CD34+ cells (n= 1). Together these ﬁndings indicate that
VMP1 is overexpressed in a subset of primary AML
CD34+ cells.
VMP1 knockdown in HSPCs results in inhibition of
autophagy and an impaired in vitro expansion and in vivo
engraftment
To investigate the functional role of VMP1 in HSPCs
and their progeny, human CB-derived CD34+ cells were
transduced with lentiviral shRNAs targeting VMP1 and
subsequently cultured in vitro or transplanted in vivo (Fig.
2a). A panel of ﬁve shRNAs was tested, of which two were
selected based on their efﬁcacy. Knockdown of VMP1 in
CB CD34+ cells was conﬁrmed at the mRNA and protein
level with both shVMP1#1 and shVMP1#2 (Fig. 2b).
Knockdown of VMP1 resulted in inhibition of the
autophagic-ﬂux as determined by relative accumulation of
Cyto-ID after HCQ treatment at day 7 during both
myeloid and erythroid liquid cultures (Supplemental Fig.
S1A). As reported previously6, the autophagic-ﬂux was
higher under erythroid- compared to myeloid-culture
conditions (Supplemental Fig. S1A). A signiﬁcant reduc-
tion in erythroid progenitor (BFU-E) frequency was
observed in in vitro colony assays upon knockdown of
VMP1 (Fig. 2c), while no change in myeloid colony for-
mation was observed. However, a reduction in relative
expansion was observed upon knockdown of VMP1 under
both erythroid and myeloid liquid culture conditions (Fig.
2d).
To assess whether VMP1 knockdown would affect the
differentiation potential of CB CD34+ cells, the expres-
sion of myeloid (CD14, CD15) and erythroid differentia-
tion markers (CD71, CD235A) were analysed using ﬂow
cytometry. This revealed only a minor delay in CD14
expression at day 8 (Supplemental Fig. S1B), but a
Fig. 1 VMP1 expression is increased in a subset of AMLs. a Expression of VMP1 and Beclin-1 in mononuclear primary AML cells acquired from the
publicly available expression dataset Bloodspot. HSPC is deﬁned as the combined fractions of HSC, MMP, CMP, GMP and MEP. b Gene expression of
VMP1 determined by quantitative RT-PCR in normal bone marrow (NBM) CD34+ cells (n= 15), AMLs with myeloid (n= 17) or monocytic
characteristics (n= 14). c Western Blot showing variation in VMP1 protein levels in different AMLs (n= 9), β-actin was used as control and VMP1/
β-actin levels are shown relative to AML1. Triangles, squares or circles indicate AMLs with a myeloid or monocytic, respectively. d Correlation
between VMP1 mRNA levels and protein levels in primary AML CD34+ cells (n= 9, square symbols), CB CD34+ cells (n= 2, circles) and NBM CD34+
cells (n= 1, triangle). Error bars represent SD; * or *** represents p < .05 or p < .001, respectively
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stronger effect on terminal erythroid differentiation
(Supplemental Fig. S1C). To study the long-term effects of
VMP1 knock-down in the context of the micro-environ-
ment, transduced CD34+ HSPCs were cultured on MS5
bone marrow stromal co-cultures, in which VMP1
knockdown resulted in reduced expansion, as determined
by the decline in percentage of mCherry positive cells
(Supplemental Fig. S1D). The negative phenotype of
shVMP1-transduced HSPCs was at least in part caused by
increased apoptosis (Supplemental Fig. S1E), while cell
cycle progression was not affected (Supplemental Fig.
S1F). To assess whether VMP1 knockdown also affected
in vivo engraftment, unsorted shSCR or shVMP1-
mCherry-transduced CB CD34+ cells were transplanted
into immunodeﬁcient NSG mice (Fig. 2a). Transplanted
CD34+ cells were ~60% mCherry-positive. Engraftment,
as determined by the percentage huCD45 in peripheral
blood, was signiﬁcantly reduced in shVMP1 mice com-
pared to controls (Fig. 2e, left panel). While mCherry
levels for shSCR remained stable around ~60%, the con-
tribution of the shVMP1 transduced cells to the engrafted
cells over time was signiﬁcantly reduced in mice with
transplanted shVMP1 CD34+ cells, compared to controls
(Fig. 2e, right panels). At sacriﬁce, high engraftment levels
in bone marrow, spleen and liver were observed, and the
contribution of shSCR-mCherry transduced cells within
the CD45 compartment was around ~60% in all analyzed
organs (Supplemental Fig. S1G, left panel). In contrast,
the percentage of shVMP1-mCherry transduced cells
within the CD45 compartment was strongly reduced
(Supplemental Fig. 1G, right panel). Together these
ﬁndings indicate that knockdown of VMP1 inhibits
autophagic-ﬂux and results in reduced expansion of
HSPC, delayed differentiation and an impaired long-term
engraftment in vivo.
VMP1 knockdown results in inhibition of autophagy,
impaired expansion, increased apoptosis and reduced cell
cycle progression in leukemic cells
Because VMP1 was shown to be differentially expressed
in primary leukemic CD34+ cells and leukemic cell lines
(Fig. 1, Supplementary Fig. 2A), the consequences of
VMP1 modulation were assessed in leukemic cells. First,
leukemic cell lines with previously determined autophagy
activity11 were transduced with shVMP1 or shSCR lenti-
vectors and knockdown efﬁciencies were conﬁrmed at the
Fig. 2 VMP1 knockdown in HSPCs results in inhibition of autophagy and an impaired in vitro expansion and in vivo engraftment. a
Experimental scheme, shSCR-mCherry or shVMP1-mCherry transduced cord blood (CB) CD34+ cells were cultured in vitro under myeloid or erythroid
liquid culture conditions or injected IV in sub-lethally irradiated NSG mice. Bleeds were performed at week 5, 8, and 12 after injection and analysed by
FACS. b Knockdown efﬁciency of VMP1 was determined by quantitative RT–PCR and Western blotting of CB CD34+ cells transduced with shSCR,
shVMP1 #1 or shVMP1 #2. c CFC assay with freshly sorted shSCR or shVMP1 #1 transduced CB CD34+ cells (n= 2). d Representative graph showing
relative expansion of shVMP1 transduced CB CD34+ cells under myeloid or erythroid permissive liquid culture conditions, shSCR transduced cells
were used as control (n= 2). e Percentage of engraftment represented by huCD45 percentage (left graph) and the percentage mCherry within the
huCD45+ population (right graph). Each dot represents data from a single mouse, n= 5 for each group. Error bars represent SD; *, ** or *** represents
p < .05, p < .01 or p < .001, respectively
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protein level, while BCL-2 levels were not affected (Fig.
3a). Knockdown of VMP1 was associated with impaired
autophagy, reﬂected by accumulation of SQSTM1/p62
(Fig. 3a) and reduced accumulation of LC3 puncta after
HCQ treatment33 (Fig. 3b, Supplemental Fig. S2B). The
knockdown of VMP1 had a strong impact on cell growth
(Fig. 3c), which was at least in part due to increased
apoptosis, as determined by annexin-V positivity (Fig. 3d).
The addition of the pan caspase inhibitor ZVAD-FMK
partially rescued the observed phenotype (Supplemental
Fig. S2C). In addition, cell cycle analysis showed that cells
accumulated in G1 phase signiﬁcantly (Fig. 3e). Next,
AML patient-derived CD34+ (n= 3) cells were trans-
duced with shVMP1-mCherry or shSCR-mCherry. The
Fig. 3 VMP1 knockdown results in inhibition of autophagy, impaired expansion, increased apoptosis and reduced cell cycle progression in
leukemic cells. a Western blot analysis of VMP1, BCL-2, and p62/SQSTM1 protein levels after knockdown of VMP1, β-actin was used as control. In
addition, the quantiﬁcation of the relative level of VMP1, BCL-2 and p62 are depicted. For each cell line, the protein levels of shVMP1 transduced cells
were normalized to the protein levels in shSCR transduced control cells. b Left panel, representative pictures showing GFP-LC3 puncta in shSCR or
shVMP1 transduced OCIM3 cells treated with or without HCQ. Dapi staining was used to count the number of cells. Right panel, quantiﬁcation of
GFP-LC3 puncta using ImageJ software. c Cell growth in time of shSCR or shVMP1 transduced leukemic cell lines; HL60, OCIM3, MOLM13 and THP1
(n= 3). d Graph showing percentage of annexin-V positive cells of shSCR or shVMP1 transduced leukemic cell lines (n= 3, day 6). e Cell cycle analysis
after Hoechst staining of shSCR or shVMP1 transduced leukemic cells (n= 2, day 6). The * in G1-phase of shVMP1 transduced leukemic cell lines
indicates a signiﬁcant difference compared to shSCR control. f Relative expansion of AML CD34+ cells after knockdown of VMP1 (n= 3) cultured on a
MS5 stromal layer. shSCR transduced AML CD34+ cells were used as control. Error bars represent SD; *, ** or *** represents p < .05, p < .01 or p < .001,
respectively
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unsorted cells were cultured long-term in MS5 bone
marrow stromal cocultures. The transduction efﬁciency in
AML CD34+ cells was between 20–60% and comparable
between shSCR and shVMP1 within a single AML sample
(Supplemental Fig. S2D). After 4 days of culture the
knockdown of VMP1 was 33 and 48% in AML10 and
AML12 respectively. Similar to leukemic cell lines,
knockdown of VMP1 resulted in decreased expansion of
primary AML CD34+ cells, relative to scrambled control
(Fig. 3f). Together, these results indicate that VMP1 is
essential for survival and proliferation of leukemic cell
lines and patient-derived AML CD34+ cells.
Overexpression of VMP1 increases autophagic-ﬂux in
leukemic cells and is involved in mitochondrial turnover
To study the consequences of high expression of VMP1
on normal and leukemic hematopoietic cells, a lentiviral
VMP1-Blueberry overexpression vector (VMP1-OE) was
constructed, and overexpression of VMP1 was conﬁrmed
at the protein level (Fig. 4a). Overexpression resulted in
reduced p62/SQSTM1 protein levels. (Fig. 4a). Decreased
p62/SQSTM1 accumulation was conﬁrmed by blocking
autophagy at a late stage using HCQ (Supplemental Fig.
S3A). In addition, overexpression of VMP1 resulted in
increased relative Cyto-ID MFI, which reﬂects a higher
LC3-dependent autophagy activity (Supplemental Fig.
S3B). Next, leukemic cell lines expressing the mCherry-
GFP-LC3 autophagy reporter were transduced with
control or VMP1-OE cells to assess the impact on the
autophagy ﬂux. An increased mCherry/GFP ratio was
observed in OCIM3 and THP1 cells overexpressing
VMP1, conﬁrming that the LC3-dependent autophagy-
ﬂux was increased (Fig. 4b–c). The increased autophagy
did not affect the cell proliferation of the cell lines.
To obtain more insight into the role of VMP1 in AML,
two large AML expression datasets28,29 were analysed
using the R2 Genomics Analysis and Visualization Plat-
form. Gene ontology analyses (GO) was performed on
genes correlating with VMP1 expression. GO analysis
revealed that positively correlated genes were enriched for
the GO terms lysosome, vacuole and vesicle transport,
while inversely correlated genes were enriched for the GO
terms mitochondrion, DNA replication, ATP binding,
apoptosis and cell cycle (Fig. 4d). Because high VMP1
expression in AML cells is inversely correlated with gene
signatures associated with mitochondria (Fig. 4d, right
panel), mitochondrial function was assessed after mod-
ulation of VMP1 expression. Overexpression of VMP1 led
to a signiﬁcant decrease in mitochondrial DNA (mtDNA)
copy number relative to nuclear DNA (nucDNA) in
OCIM3 and THP1 cells (Fig. 4e). In line with these
results, TOM20 which is a marker for mitochondrial
mass, was decreased after overexpression of VMP1 (Fig.
4a). Conversely, shVMP1 transduced leukemic cells had
an increase in mtDNA copy number in cell lines. (Sup-
plemental Fig. S3C). However, this increase was not
Fig. 4 Overexpression of VMP1 increases autophagic-ﬂux in leukemic cells and is involved in mitochondrial turnover. a Western blot
analysis of TOM20, p62 and VMP1 in OCIM3 and THP1 cells overexpressing VMP1 (VMP1-OE) or control. b The mCherry/GFP ratio determined in
mCherry-GFP-LC3 expressing leukemic cell lines, transduced with control or VMP1 OE. c Representative FACS of the mCherry/GFP ratio analysis in
OCIM3 and THP1 cells. d Gene ontology analysis (David) was performed on two large AML patient gene expression datasets. Figures showing p-
values of enriched gene sets, positively (left graph) or inversely (right graph) correlated with VMP1 expression in AMLs. e Mitochondrial copy number
in OCIM3 and THP1 cells with VMP1-OE or control. Error bars represent SD; * or ** represents p < .05 or p < .01, respectively
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observed in MOLM13 cells. Together these ﬁndings
indicate that overexpression of VMP1 is involved in
mitochondrial turnover.
Ultrastructural analysis and mitochondrial function in
OCIM3 cells after VMP1 modulation
To obtain more insight into the involvement of VMP1
in mitochondrial quality control, we analyzed OCIM3
cells ultrastructurally with electron microscopy (EM) after
lentiviral overexpression or knockdown of VMP1. OCIM3
cells overexpressing VMP1 displayed a reduction in the
number of mitochondrial structures compared to control
cells (Fig. 5a, p= < .01). Representative ultrastructural
images are shown in Fig. 5b. In the shVMP1-transduced
OCIM3 cells mitochondria were on average ~24% larger
and swollen compared to control (Supplemental Fig. 4A).
Moreover, in contrast to VMP1-OE, cells with knock-
down of VMP1 had elevated numbers of mitochondrial
structures (Fig. 5c–d, p= < .05). In addition, the mito-
chondrial function was analyzed after VMP1 modulation.
The mitochondrial membrane potential (MMP) measured
by tetramethylrhodamine (TMRM) was signiﬁcantly
increased in OCIM3 cells overexpressing VMP1, while
there was a trend for reduced MMP upon VMP1
knockdown (Fig. 5e). Although the number of mito-
chondria in VMP1 overexpressing cells was reduced (Fig.
4), these cells had higher levels of ATP content (Fig. 5f).
Conversely, knockdown of VMP1 resulted in decreased
ATP production with concomitant increased ROS levels,
indicating a loss in mitochondrial function (Fig. 5f, Sup-
plemental Fig. S4B–C). In line with these results,
increased ROS levels were also observed with the Mito-
SOX tracer conﬁrming that ROS is of mitochondria origin
(Supplementary Fig. S4, D). Additional analysis by EM
revealed that cells overexpressing VMP1 had an increased
number of onion-like multilamellar membrane structures,
also called whorls (Fig. 5a, g, 1.5 fold, p= < .05). These
structures are associated with lysosomal mediated
degradation of intra-cellular parts, also termed the
degradative compartment34, and are associated with an
increased autophagy ﬂux. Together, the increase in
autophagy, the reduced number of mitochondria struc-
tures in response to VMP1 overexpression are indicative
of increased turnover of mitochondria.
Overexpression of VMP1 interferes with venetoclax
induced apoptosis
BCL-2 protein family members regulate apoptosis by
controlling the permeability of mitochondria35. Interest-
ingly, VMP1 has been shown to contain a BH3-binding
domain, which is an important characteristic of the BCL-2
protein family36. The speciﬁc BCL-2 inhibitor venetoclax
has been shown to disrupt the BH3 dependent BCL-2/
Beclin-1 interaction, thereby activating autophagy37,38.
First, we studied the consequences for autophagy activity
after venetoclax treatment in the context of high VMP1
expression. As expected, in THP1 cells p62 levels declined
in a dose-dependent manner with increasing concentra-
tion of venetoclax, which is indicative for increased
autophagic-ﬂux (Fig. 6a). Basal p62 levels were reduced in
THP1 cells overexpressing VMP1, while p62 levels further
declined with increasing concentrations of venetoclax
(Fig. 6a). Next, we evaluated the effect of high VMP1
expression on the threshold for mitochondrial outer
membrane permeabilization (MOMP). The initiation of
MOMP is preceded by loss of mitochondrial membrane
potential (MMP) and results in caspase-dependent
apoptosis35. Leukemic cells overexpressing either BCL-2
or VMP1 were treated with increasing concentrations of
venetoclax and the MMP was determined after tetra-
methylrhodamine (TMRM) staining in the context of
BCL-2 and VMP1 overexpression. Venetoclax-induced
loss of MMP could be partially rescued by VMP1 or BCL-
2 overexpression (Fig. 6b and Supplemental Fig. 5A). In
addition, venetoclax induced apoptotic response in HL60
and THP1 cells, as determined by caspase-3 cleavage and
annexin-V staining, could partially be rescued by over-
expressing BCL-2 or VMP1 (Fig. 6c–d and Supplemental
Fig. S5A). Inhibition of autophagy with HCQ did not
reverse the VMP1-medated rescue of venetoclax cyto-
toxicity (Supplementary Fig. 5B). Next, we validated
whether inhibition of autophagy by knocking down VMP1
or the essential autophagy gene ATG7 would affect
venetoclax mediated cell death. In contrast to over-
expression of VMP1, knockdown of VMP1 or ATG7 in
combination with venetoclax treatment resulted in
enhanced cell death, although no synergistic effects were
observed with the combination (shVMP1 31 ± 3.7% vs.
shVMP1 plus venetoclax 53 ± 3.7% reduction in survival
p= < 0.05 and shATG7 18% ± 2.8% vs. shATG7 plus
venetoclax 45 ± 2.5% reduction in survival p= < 0.01).
To study the speciﬁcity of effects, leukemic cell lines
were treated with the speciﬁc and potent MCL-1 inhibitor
S6384539. In contrast to BCL-2 overexpression, VMP1
overexpression did not rescue S63845-mediated apoptosis
(Supplemental Fig. S5C). Finally we tested if high VMP1
expression would affect BCL-2 expression or cellular
localization. BCL-2 protein levels did not change after
treatment with increasing concentrations of venetoclax in
VMP1 overexpressing cells (Supplemental Fig. S5D).
Next, cellular fractionation was performed of HL60 cells
overexpressing VMP1 or control vector. From total cell
lysates the mitochondrial (P10), cytosolic S100 or endo-
plasmic reticulum fraction (P100) were puriﬁed. Pur-
iﬁcation of the mitochondrial fraction and cytosolic
fraction was conﬁrmed by enrichment for COX-IV or
β-actin, respectively. Interestingly, under all tested con-
ditions BCL-2 was primarily present in the mitochondrial
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Fig. 5 Ultrastructural analysis and mitochondrial function in OCIM3 cells after VMP1 modulation. a Quantiﬁcation of mitochondrial structures
per section in OCIM3 cells transduced with lentiviral vectors for overexpression of VMP1 (VMP1-OE) or control (n > 32 sections per group).
b Representative ultrastructural pictures of OCI3M cells overexpression VMP1 or control, N= nucleus, L= lipid droplet, G= Golgi, green arrow=
whorls/degradative compartments. The blue (control) or green (VMP1-OE) dotted lines indicate mitochondrial structures. c Quantiﬁcation of
mitochondrial structures per section in OCIM3 cells with knockdown of VMP1 (shVMP1) or control vectors (n > 32 sections per group). d Representative
ultrastructural pictures of OCI3M cells with knockdown of VMP1 or control. N= nucleus. The blue (control) or red (shVMP1) dotted lines indicate
mitochondrial structures. e FACS analysis of mitochondrial membrane potential (MMP) after tetramethylrhodamine (TMRM) staining in OCIM3 with
VMP1 overexpression, VMP1 knockdown or control (n= 3). f ATP levels measured in OCIM3 with VMP1 overexpression, VMP1 knockdown or control
(n= 4). g Electron microscopy, quantiﬁcation of onion-like multilamellar membrane structures called degradative compartments per section of
OCIM3 cells, transduced with VMP-OE or control (n ≤ 35 cells per group). Examples of degradative compartments are indicated by green arrows in
b right panels. Error bars represent SD; * or ** represents p < .05 or p < .01, respectively
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fraction, suggesting that relocalization of BCL-2 did not
cause the observed resistance against venetoclax-
mediated cell death in high VMP1 expressing cells (Fig.
6e).
Together, these data indicate that overexpression of
BCL-2 and VMP1 increase the threshold for venetoclax-
mediated loss of MOMP, thereby reducing apoptosis-
mediated cell death.
Discussion
The present study indicates that VMP1 is involved in
autophagy and mitochondrial turn-over in normal
hematopoietic and leukemic cells. Blocking VMP1
expression impairs the autophagy ﬂux, coinciding with
reduced proliferation and survival of normal and leukemic
HSPC and impaired in vivo engraftment. Previous studies
on VMP1 function have been done primarily in solid
tumors40,41, but gene expression studies in hematopoietic
cells showed that VMP1 is differentially expressed in
hematopoietic cell lineages, including HSPCs. In the
leukemic counterpart, VMP1 can be overexpressed in all
AML subcategories independent of the molecular and
genetic makeup. Functional studies have shown that
VMP1 disrupts the binding of BCL-2 to Beclin-1 and
Fig. 6 Overexpression of VMP1 interferes with venetoclax induced apoptosis. a Western blot of p62 in THP1 cells overexpressing VMP1 or
control treated with different concentrations of venetoclax, β-actin was used as control. (n= 2) b Bar graph showing the percentage of TMRM
positive cells. HL60 cells overexpressing VMP1, BCL-2 or control were incubated for 24 h with different concentrations of venetoclax. (n= 3) cWestern
Blot showing cleaved caspase 3 in HL60 and THP1 cells overexpressing VMP1 or control after 24 h incubation with 25 nM venetoclax (n= 2).
d Leukemic cell lines with lentiviral overexpression of VMP1, BCL-2 or control were treated 24 h with venetoclax and apoptosis was measured by
annexin-V staining with FACS (n= 4). e Western blot showing BCL-2, COX-IV, and β-Actin in the mitochondrial (P10), cytosolic (S100) or endoplasmic
reticulum (P100) fractions of HL60 cells overexpressing VMP1 or control, treated with or without venetoclax. Error bars represent SD; *, ** or ***
represents p < .05, p < .01 or p < .001, respectively
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consequently de-represses autophagy23. These ﬁndings
are in line with our results showing that reduced VMP1
expression resulted in inhibition of LC3-dependent
autophagy, while overexpression enhanced LC3-
dependent autophagy-ﬂux. This would also suggest that
AMLs with high VMP1 expression are primed for robust
autophagy activation in response to cellular stress. In
addition, our study showed that high VMP1 expression is
inversely correlated with genes enriched for the GO-terms
associated with mitochondria, which is in line with studies
in Hela cells showing that VMP1 co-localizes with mito-
chondrial structures34,37. Based on functional studies and
electron microscopy, our results suggest that VMP1 reg-
ulates mitochondria quantity and quality by affecting
mitophagy. Higher VMP1 expression reduces mitochon-
drial copy number and TOM20 expression and increases
mitochondrial membrane potential and ATP production.
This is indicative for improvement in quality of the
remaining mitochondria, while reduced VMP1 expression
generated the opposite results. In addition, knockdown of
VMP1 resulted in swollen mitochondria and increased
ROS levels, which is most likely the consequence of
accumulating (dysfunction) mitochondria, resulting in cell
death which coincides with the loss of mitochondrial
membrane potential and ATP levels. Previous studies with
ATG12, ATG5 or ATG7 knockout mice have reported
comparable results: accumulating dysfunctional mito-
chondria and ROS5,42–44.
The higher expression of VMP1 in AML CD34+ cells
might be protective for AML cells in the hypoxic bone
marrow micro-environment, where control of mitochon-
dria content and ROS production by autophagy is crucial
for maintaining an immature phenotype5. Similar to other
pro-autophagy genes45, VMP1 expression can be upre-
gulated under hypoxia46. However, in leukemic cell lines
TOM20 and VMP1 protein levels both declined when the
cells were cultured under hypoxia (data not shown).
Therefore it is more likely that the mitochondrial turn-
over during hypoxia is controlled by BNIP3 and BNIP3-L,
which demonstrate a strong upregulation in response to
hypoxia exposure45.
The threshold for MOMP, and consequently for
cytochrome-c release-dependent caspase activation, is
regulated by the expression level of BCL-2 protein family
members, which might account for drug resistance in a
subgroup of AML patients47–50. Recently, promising
results have been obtained with venetoclax in relapsing
AML patients in conjunction with low-dose chemother-
apy51. Predictive markers have been identiﬁed for reduced
sensitivity for venetoclax, such as increased expression of
BCL-XL or MCL-139,47,52,53. The present study indicates
that VMP1 overexpression is an additional predictive
maker for resistance against venetoclax in AML. VMP1
overexpression resulted in an increase in MMP, which
could in turn increase the threshold for venetoclax-
mediated apoptosis. Mitochondria play a central role in
regulation of apoptosis54. Cells with more mitochondrial
content where shown to be more prone to undergo
apoptosis55. Therefore, VMP1 overexpression could
potentially inhibit pro-apoptotic signalling by increased
turnover of dysfunctional mitochondria. However, these
protective effects of VMP1 are only partially regulated by
autophagy induction since HCQ did not reverse the
VMP1-mediated rescue of venetoclax induced apoptosis.
In summary, the results demonstrate that VMP1 is
essential for HSPC and AML cells and is involved in
mitochondrial quality control. High VMP1 expression is
protective against loss of membrane potential and apop-
tosis induced by venetoclax.
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